StockData
AbbVie Inc. logo

AbbVie Inc.

ABBVNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 3, 2026Score 10/3089% above fair value
$288.84−6.05 (-2.05%)

Close on Nov 2, 2026Market cap $510.41BP/E 81.6Yield 2.30%

AbbVie Creon (pancrelipase) by Year

Creon (pancrelipase) — Worldwide operational (constant-currency) growth YoY (%) (%)

AbbVie Creon (pancrelipase): 9.3% in FY2025, up 0.2 pts from a year earlier.

Latest, FY2025
9.3%
Period ended Dec 31, 2025
Change on a year earlier
+0.2 pts
9.1% in FY2024
History
7 years
Since FY2017
Sources
7
Documents cited below

Where the FY2025 figure comes from

“|| Creon | 1,512 | — | 1,512 | 9.3 | n/m | 9.3 | n/m | 9.3”

Source: Form 8-K (abbv-20251231xexhibit991.htm, filed 2026-02-04) ↗

Reported in Form 8-K Key Product Revenues Schedule.

Annual history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedCreon (pancrelipase) — Worldwide operational (constant-currency) growth YoY (%) (%)Year on yearSource
FY2025Dec 31, 20259.3%+0.2 ptsForm 8-K (abbv-20251231xexhibit991.htm, filed 2026-02-04) ↗
FY2024Dec 31, 20249.1%+9.9 ptsForm 8-K (abbv-20241231xexhibit991.htm, filed 2025-01-31) ↗
FY2023Dec 31, 2023-0.8%-8.1 ptsForm 8-K (abbv-20231231xexhibit991.htm, filed 2024-02-02) ↗
FY2022Dec 31, 20227.3%–Form 8-K (abbv-20221231xexhibit991.htm, filed 2023-02-09) ↗
FY2019Dec 31, 201912.2%+0.5 ptsForm 8-K (abbv-20191231xexhibit9.htm, filed 2020-02-07) ↗
FY2018Dec 31, 201811.7%-2.2 ptsForm 8-K (abbv-20181231xexhibit991.htm, filed 2019-01-25) ↗
FY2017Dec 31, 201713.9%–Form 8-K (abbv-20171231xexhibit991.htm, filed 2018-01-26) ↗

Cite this data

StockData. (2026). AbbVie Creon (pancrelipase) (%), annual FY2017–FY2025 [Data set]. Compiled from AbbVie SEC filings and investor materials. https://stockdatahq.com/stocks/abbv/kpis/creon-ww-op-yoy

See every metric in the AbbVie KPI table. Data updated Oct 26, 2026.